Following implantation of a cardiac stent, patients are often given dual anti-platelet treatment (DAPT) to prevent re-occlusion of the treated artery. However, if a patient requires additional surgery soon after implantation, early discontinuation of DAPT is required.
Hong Kong-based OrbusNeich has announced the results of a clinical trial which showed that its Genous endothelial progenitor cell (EPC) capture stent is safe for use in patients requiring early discontinuation of DAPT. The Genous technology traps EPCs at the implantation site, which accelerates the artery’s natural healing process and promotes even growth of an endothelial layer over the stent.
From the press release:
In the single-center study, patients treated with the Genous endothelial progenitor cell (EPC) capture stent discontinued DAPT between 21 and 30 days post-procedure and underwent non-cardiac surgical intervention within 60 days of percutaneous coronary intervention (PCI). Despite the shortened period of DAPT administration, there were no cases of stent thrombosis (ST) observed in patients treated with Genous. Additionally, no cases of perioperative major adverse cardiac events (MACE) were detected.
Product page: Genous Technology…
Study abstract at Minerva Medica: Rationale and results of percutaneous coronary revascularization with endothelial progenitor cell capture stent in high-risk patients requiring undeferrable non-cardiac surgery